Read by QxMD icon Read

HCC Recurrence

Michael Praktiknjo, Viktoria Krabbe, Alessandra Pohlmann, Matthias Sampels, Christian Jansen, Carsten Meyer, Christian P Strassburg, Jonel Trebicka, Maria A Gonzalez Carmona
BACKGROUND: Early information on treatment response of HCC to local ablative therapy is crucial. Elastography as a non-invasive method has recently been shown to play a potential role in distinguishing between benign and malignant liver lesions. Elastography of hepatocellular carcinoma (HCC) in early response to local ablative therapy has not been studied to date. METHODS: We prospectively included a cohort of 14 patients with diagnosis of HCC who were treated with local ablative therapy (transarterial chemoembolization, TACE and/or radiofrequency ablation, RFA)...
2018: PloS One
Yufu Tang, Ruoyu Wang, Yibing Zhang, Shenhui Lin, Na Qiao, Zhongyi Sun, Shuqun Cheng, Wenping Zhou
BACKGROUND/AIMS: 14-3-3ζ is involved in the regulation of PI3K/Akt pathway which is closely associated with carcinogenesis. However, the clinical significance of combined detection of 14-3-3ζ and p-Akt in hepatocellular carcinoma (HCC) remains unclear. METHODS: Two-hundred pairs of HCC and adjacent liver specimens were subjected to tissue microarray. The association of 14-3-3ζ and p-Akt levels with the postoperative survival and recurrence in HCC patients was analyzed with univariate and multivariate methods...
February 7, 2018: Cellular Physiology and Biochemistry
Xiao-Meng Dai, Sheng-Li Yang, Xiu-Mei Zheng, George G Chen, Jing Chen, Tao Zhang
Hepatocellular carcinoma (HCC) is a highly heterogeneous type of tumor, which may be caused by the stem/progenitor cell features of particular HCC cells. Recent studies have subclassified HCC into different prognostic subtypes according to just one stemness-associated marker. However, one stemness-associated marker is not sufficient to clearly define cancer stem cells, or to decipher the heterogeneous nature of HCC. For a more precise subtype classification for prognostic application, a combination of multiple stemness-associated markers is required...
March 2018: Oncology Letters
Lige Qiu, Hailiang Li, Sirui Fu, Xiaofang Chen, Ligong Lu
Liver cancer stem cells (LCSCs) have important roles in the occurrence, development, recurrence, therapy resistance and metastasis of hepatocellular carcinoma (HCC). Therefore, intensive studies are undergoing to identify the mechanisms by which LCSCs contribute to HCC invasion and metastasis, and to design more efficient treatments for this disease. With continuous efforts in LCSC research over the years, therapies targeting LCSCs are thought to have great potential for the clinical treatment and prognosis of liver cancer...
February 2018: Oncology Letters
Yong Wang, Yahui Liu, Jianshuai Jiang, Hanbin Cui
The existence of cancer stem cells (CSCs) or cancer stem-like cells (CSLCs) is regarded as the cause of tumor formation and recurrence. Matrine has been reported to exhibit antitumor effects in cancer cells. In the present study, a preliminary study was performed on the mechanisms of matrine on hepatocellular carcinoma (HCC) stem-like cells. The HCC SMMC-7721 cell line was cultured in tumor stem cell-specific medium to form spheres, and different concentrations (1, 2 and 5 mg/kg) of cisplatin were then used in order to purify the most drug-resistant cells, which were used as CSLCs...
February 2018: Oncology Letters
Ander Ernaga Lorea, Iranzu Migueliz Bermejo, Emma Anda Apiñániz, Javier Pineda Arribas, Marta Toni García, Juan Pablo Martínez de Esteban, Ana María Insausti Serrano
INTRODUCTION: Hürthle cell carcinoma (HCC) is an uncommon thyroid cancer historically considered to be a variant of follicular thyroid carcinoma (FTC). The aim of this study was to assess the differences between these groups in terms of clinical factors and prognoses. PATIENTS AND METHODS: A total of 230 patients (153 with FTC and 77 with HCC) with a median follow-up of 13.4 years were studied. The different characteristics were compared using SPSS version 20 statistical software...
February 9, 2018: Endocrinología, Diabetes y Nutrición
Jiannis Vlachogiannakos, George V Papatheodoridis
As current treatment options almost never achieve eradication of hepatitis B virus (HBV), the most realistic goal for HBV treatment is persistent inhibition of viral replication and ALT normalization. Thus, the decision to start treatment should be based on careful patient selection and individualized decisions. Treatment is generally indicated in chronic hepatitis B patients with HBV DNA >2000 IU/mL, elevated ALT and/or at least moderate histological lesions, while all patients with cirrhosis and detectable HBV DNA should be treated...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Bruno Roche, Audrey Coilly, Jean Charles Duclos-Vallee, Didier Samuel
Hepatitis C virus infection is a major cause of chronic hepatitis resulting in cirrhosis and hepatocellular carcinoma (HCC). The recent introduction of direct acting antivirals (DAA), results in sustained virological response (SVR) rates of >90% in treated patients whatever the stage of liver fibrosis with an excellent safety profile. This major advancement has allowed treatment of a larger number of patients, some with more advanced liver dysfunction and a higher risk of HCC. An SVR is associated with a reduced risk of hepatic decompensation, the need for liver transplantation and both liver-related and overall mortality...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
R Tang, J-C Wu, L-M Zheng, Z-R Li, K-L Zhou, Z-S Zhang, D-F Xu, C Chen
OBJECTIVE: This study aimed at exploring the expression and prognostic values of a novel long noncoding RNA RUSC1-AS-N in hepatocellular carcinoma (HCC), and to investigate the biological roles of RUSC1-AS-N in HCC cells. PATIENTS AND METHODS: RUSC1-AS-N expression in public available microarray data was analyzed. The expression of RUSC1-AS-N in our cohort containing 66 HCC tissues and paired adjacent non-cancerous hepatic tissues was measured by qRT-PCR. The correlation between RUSC1-AS-N expression and clinicopathological characteristics was evaluated by Pearson χ2-test...
January 2018: European Review for Medical and Pharmacological Sciences
Tae Hyun Kim, Joong-Won Park, Bo Hyun Kim, Dae Yong Kim, Sung Ho Moon, Sang Soo Kim, Ju Hee Lee, Sang Myung Woo, Young-Hwan Koh, Woo Jin Lee, Chang-Min Kim
Objective: To evaluate the optimal time of tumour response and effectiveness of hypofractionated proton beam therapy (PBT) for hepatocellular carcinoma (HCC). Results: Overall, treatment was well tolerated with no grade toxicity ≥3. Of 71 patients, 66 patients (93%) eventually reached complete response (CR) after PBT: 93.9% (62 of 66) of patients who reached CR within 12 months, and the remaining 4 patients (6.1%) reached CR at 12.5, 16.2, 19.1 and 21.7 months, respectively...
January 9, 2018: Oncotarget
Jun Ho Lee, Jae Hee Suh, Soo Youn Choi, Hyun Je Kang, Hwan Hee Lee, Byeong Jin Ye, Gap Ryol Lee, Seok Won Jung, Chang Jae Kim, Whaseon Lee-Kwon, Jiyoung Park, Kyungjae Myung, Neung Hwa Park, Hyug Moo Kwon
OBJECTIVES: Hepatocellular carcinoma (HCC) is a common cancer with high rate of recurrence and mortality. Diverse aetiological agents and wide heterogeneity in individual tumours impede effective and personalised treatment. Tonicity-responsive enhancer-binding protein (TonEBP) is a transcriptional cofactor for the expression of proinflammatory genes. Although inflammation is intimately associated with the pathogenesis of HCC, the role of TonEBP is unknown. We aimed to identify function of TonEBP in HCC...
February 2, 2018: Gut
Jian Zhou, Zheng Wang, Zhenggang Ren, Yi Chen, Jie Hu, Guo-Huan Yang, Lei Yu, Xin-Rong Yang, Ao Huang, Xin Zhang, Shao Lai Zhou, Hui-Chuan Sun, Yan Hong Wang, Ning Ling Ge, Xiao-Yu Xu, Zhaoyou Tang, Wan Yee Lau, Jia Fan, Jiping Wang
PURPOSE: The survival of patients with hepatocellular carcinoma (HCC) recurrence after curative resection are usually poor. We sought to evaluate the safety and efficacy of adjuvant transarterial chemoembolization (TACE) in HBV-related HCC patients with an intermediate (a single tumor larger than 5 cm without microvascular invasion) or high risk (a single tumor with microvascular invasion, or two or three tumors) of recurrence. EXPERIMENTAL DESIGN: In this randomized phase 3 trial, 280 eligible patients were assigned to adjuvant TACE (n=140) or no adjuvant treatment (control; n = 140) groups...
February 2, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Qian Wang, Gang Wang, Yi Wang, Chaoxu Liu, Xianli He
BACKGROUND: The mammalian AlkB homolog (ALKBH) protein family has been reported to promote tumor cell invasion and metastasis of human cancer. However, the expression status and clinical significance of ALKBH3 in hepatocellular carcinoma (HCC) has not been reported yet. METHODS: In the present study, we investigated the protein expression of ALKBH3 by immunohistochemistry assay, evaluated its association with tumor progression, recurrence and prognosis in 272 patients with HCC...
February 7, 2018: Journal of Gastroenterology and Hepatology
Ah Yeong Kim, Dong Hyun Sinn, Woo Kyoung Jeong, Young Kon Kim, Tae Wook Kang, Sang Yun Ha, Chul Keun Park, Gyu Seong Choi, Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Min-Ji Kim, Insuk Sohn, Sin-Ho Jung, Seung Woon Paik, Won Jae Lee
BACKGROUND AND AIMS: Hepatobiliary MRI provides additional information beyond size and number of the tumor, and may have prognostic implication. We tested whether pre-transplant radiologic features on MRI can stratify risk of tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC). METHODS: A total of 100 liver transplanted patients who had preoperative gadoxetic acid-enhanced MRI, including the hepatobiliary phase (HBP), were reviewed for size, number, morphologic type (e...
February 2, 2018: Journal of Hepatology
Kayvan Mohkam, Paul-Noël Dumont, Anne-Frédérique Manichon, Jean-Christophe Jouvet, Loïc Boussel, Philippe Merle, Christian Ducerf, Mickaël Lesurtel, Agnès Rode, Jean-Yves Mabrut
BACKGROUND: No touch multibipolar radiofrequency ablation (NTM-RFA) represents a novel therapy that surpasses standard RFA for hepatocellular carcinoma (HCC), but it was never compared to surgical resection (SR). We aimed to compare outcomes of NTM-RFA and SR for intermediate-sized HCC. METHODS: Between 2012 and 2016, outcomes of patients primarily treated for solitary HCC ranging from 2 to 5 cm by NTM-RFA or SR at a single-center were compared using inverse probability of treatment weighting (IPTW)...
February 1, 2018: Journal of Hepatology
Wei Xu, Hao Liu, Zhi-Gang Liu, Hong-Sheng Wang, Fan Zhang, Hao Wang, Ji Zhang, Jing-Jing Chen, Hong-Jun Huang, Yuan Tan, Meng-Ting Cao, Jun Du, Qiu-Gui Zhang, Guan-Min Jiang
Hepatocellular carcinoma (HCC) remains the third most common cause of cancer-related mortality. Resection and transplantation are the only curative treatments available, but are greatly hampered by high recurrence rates. Histone deacetylase inhibitors (HDACIs) are considered to be promising anticancer agents in drug development. Currently, four HDACIs have been granted Food and Drug Administration (FDA) approval for cancer. HDACIs have shown significant efficacy in hematological malignancies. However, they have limited effects in epithelial cell-derived cancers, including HCC, and the mechanisms of these are not elucidated...
January 30, 2018: Cancer Letters
Paolo A Cortesi, Luca S Belli, Rita Facchetti, Chiara Mazzarelli, Giovanni Perricone, Stella De Nicola, Giancarlo Cesana, Christophe Duvoux, Lorenzo G Mantovani, Mario Strazzabosco
Different strategies of DAAs treatment are currently possible both pre and post liver-transplantation (LT). Clinical and economic consequences of these strategies still need to be adequately investigated; this study aims at assessing their cost-effectiveness. A decision-analytical model was created to simulate the progression of HCV-infected patients listed for decompensated cirrhosis (DCC) or for Hepatocellular carcinoma (HCC). Three DAAs treatment strategies were compared: (i) a 12-week course of DAAs prior to transplantation (PRE-LT), (ii) a 4-week course of DAAs starting at the time of transplantation (PERI-LT), and (iii) a 12-week course of DAAs administered at disease recurrence (POST-LT)...
February 6, 2018: Journal of Viral Hepatitis
Stacey B Prenner, Laura Kulik
PURPOSE OF REVIEW: To highlight the current data for treatment of hepatitis C virus (HCV) in patients with hepatocellular carcinoma (HCC) awaiting orthotopic liver transplant and incorporation of various factors to decide the optimal time to initiate HCV therapy. RECENT FINDINGS: Viral eradication on the waiting list has been found to lead to significant clinical improvement in approximately 20% of HCV-positive patients. However, there have been concerns raised for direct-acting antiviral (DAA) therapy in patients listed with HCC...
February 5, 2018: Current Opinion in Organ Transplantation
Myron J Tong, Alexander A Rosinski, Claiborne T Huynh, Steven S Raman, David S K Lu
Hepatocellular carcinoma (HCC) is the main cause of mortality in patients with chronic viral hepatitis (CVH). We determined the impact of surveillance and treatments on long-term outcomes in patients with CVH who developed HCC. Between 1984 and 2014, 333 patients with HCC and with hepatitis B or hepatitis C virus infection were evaluated. An adjusted lead time bias interval was added to patients with HCC who presented with HCC (no surveillance), and their survival was compared to patients whose HCC was detected by surveillance...
September 2017: Hepatology Communications
Marc Najjar, Surbhi Agrawal, Jean C Emond, Karim J Halazun
Hepatocellular carcinoma (HCC) is the most common liver malignancy and the third most common cause of cancer-related deaths. Liver resection (LR) and liver transplantation (LT) are the only curative modalities for HCC. Despite recent advances and the adoption of the Milan and University of California, San Francisco, criteria, HCC recurrence after LR and LT remains a challenge. Several markers and prognostic scores have been proposed to predict tumor aggressiveness and supplement radiological data; among them, neutrophil-lymphocyte ratio (NLR) has recently gained significant interest...
2018: Journal of Hepatocellular Carcinoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"